E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov +3 more
wiley +1 more source
Screening for liver disease in patients with diabetes: new standard of care? [PDF]
Iyer M, Asrani SK.
europepmc +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Editorial: New insights into caring for pediatric patients with cystic fibrosis
Stephanie Bui +9 more
doaj +1 more source
Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care? [PDF]
Brandts J, Marx N.
europepmc +1 more source
NKCC1: A key regulator of glioblastoma progression
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen +5 more
wiley +1 more source
Accommodation with anticancer drug shortage: A Lebanese harmful solution
Clarisse Kattan, Joseph Kattan
doaj +1 more source
Randomized Personalized Trial for Stress Management Compared to Standard of Care. [PDF]
Goodwin AM +8 more
europepmc +1 more source
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care? [PDF]
Lee JJ, Desai CS, Kim HJ.
europepmc +1 more source

